Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
about
Viral hepatitis and hepatocellular carcinomaHepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patientsHigh versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort studyRibavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominanceMolecular prognostic prediction in liver cirrhosisFactors associated with the response to interferon-based antiviral therapies for chronic hepatitis CSmad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseasesDiagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current ConsensusIgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis CA large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis CProlonged Therapy of Advanced Chronic Hepatitis C with Low-Dose PeginterferonA dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patientsAssociation between hepatitis C and hepatocellular carcinomaSurveillance for hepatocellular carcinoma.Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic interventionMedicinal prevention of gastrointestinal tumors: aspirin, Helicobacter and more?Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesMolecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPKVariation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriersDiagnosis, management, and treatment of hepatitis CFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis CScreening and surveillance for hepatocellular carcinoma: perspective of a new era?Comparison of hepatocellular carcinoma in Eastern versus Western populations.APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and CTransient elastography in clinical detection of liver cirrhosis: A systematic review and meta-analysis.Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients.Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI.Prediction of hepatocellular carcinoma incidence risk by ultrasound elastographyClinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Synchronous development of intrahepatic cholangiocarcinoma and hepatocellular carcinoma in different sites of the liver with chronic B-viral hepatitis: two case reportsTreatment of hepatitis C. The 2002 French consensus.Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data.Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system.Efficacy of splenectomy for hypersplenic patients with advanced hepatocellular carcinoma.Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia.Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia.
P2860
Q21245597-2AF6DD58-A4DB-4D17-8107-84713D66DB46Q22305832-04407917-08C2-4F9D-8451-3A063EFE3F9BQ24653596-B052A495-FB86-412B-ABF8-7C08C47C4E58Q24799492-F6E70F2D-0A37-49C3-9F55-2AAFBD45CA6BQ26777659-153250F4-270F-43BF-8348-EFC56AF540BBQ26784251-6B1F6F93-4A8A-4BC4-BE0A-202028145FB1Q26825715-48F3B914-D1ED-4E31-A946-646AB39F438FQ26863522-92026B90-3102-459D-870E-373FBCFBCD04Q27027855-0EC940FD-D7C3-4C80-A64D-9218ECBCD7A3Q27480600-310292A9-C7BC-496B-B95D-4E69BFEF7507Q27482028-C0CA7042-8524-4E08-9A7B-FD04D3881E20Q27487518-DD3D7D53-1636-42FD-B11C-214AA50F5DEBQ27488742-DFAA28FD-BB87-403B-8007-47E267AB0B5DQ27491295-DB4987BC-7CAC-4A7B-9B3F-4FBB12B60A3BQ27690269-D4B72B81-3A69-4891-B2C5-57225C3C5405Q28080281-17AF3ED3-6D91-42CD-AECA-54FF4F9B8517Q28201474-FFD89611-36C2-402D-A83F-97DCA2994E6AQ28272678-9C09E1D6-1574-441B-9388-BD94CA45DBF7Q28384866-DA6807E2-62D2-4D56-B9F9-A83931F49580Q28943479-68C8ABDF-8FF7-4F08-97DB-A8A688FB4C55Q29620656-772FC5FA-E821-4242-8CF3-668B33CFE684Q30235178-1C86E18E-73D2-4C28-8D4F-37A34FDCF3FDQ30244651-315804BD-D5AF-4380-AED3-D93BDE0AE474Q30245396-2599463D-A09F-4003-A0C6-9406E6455C53Q30250088-5BE93137-7A7C-4582-9FF5-6543F95CDD28Q30250322-BECAF18F-1E11-4538-9B5C-C80045DA0B9EQ30374701-897FA1BF-CC60-4B73-AD7A-94C229C58E58Q30374820-3B5CDB96-9DD6-408F-9FEE-7B8A2298D364Q30422199-A4BE3A71-00DA-4752-A364-4F611F5A960CQ30422395-41FD9F84-48B5-4606-AA4D-12A610AC02B2Q30438860-077E884B-F082-4859-9F38-02AB706B0F12Q30468484-5E083610-8170-4C47-9784-E82F4A61CF42Q30479629-E6ECB300-80F8-4196-B584-5C9A935EBEA6Q31145862-5C5E1A5D-8F03-4243-AE03-3A65EC34C044Q33195269-A7110A44-32B6-4846-AB93-5064957F8AD1Q33213145-6AAC4D67-1605-4B2D-8B6F-0C577613D420Q33280446-782DB023-4C3F-451F-9E24-17185831AA7AQ33380392-E25FE654-8D19-45EA-9156-07AAF7CD650DQ33380508-64AE0BC3-78C8-4348-BEE7-6C6F2BD834FBQ33383219-9E9A73DC-4B26-494F-A3C2-118731E33AA6
P2860
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Interferon therapy reduces the ...... genesis by Interferon Therapy.
@en
Interferon therapy reduces the ...... genesis by Interferon Therapy.
@nl
type
label
Interferon therapy reduces the ...... genesis by Interferon Therapy.
@en
Interferon therapy reduces the ...... genesis by Interferon Therapy.
@nl
prefLabel
Interferon therapy reduces the ...... genesis by Interferon Therapy.
@en
Interferon therapy reduces the ...... genesis by Interferon Therapy.
@nl
P2093
P1476
Interferon therapy reduces the ...... genesis by Interferon Therapy.
@en
P2093
Fujiyama S
Kinoyama S
Moriyama M
Nishiguchi S
P304
P356
10.7326/0003-4819-131-3-199908030-00003
P407
P577
1999-08-01T00:00:00Z